Ranbaxy Laboratories Ltd today said Nihon Pharmaceutical Industry Ltd, a joint venture between the company and Japan-based Nippon Chemiphar Ltd , has launched the antibiotic 'Clarithromycin' and anti-fungal 'Terbinafine' tablets in the Japanese market.
Clarithromycin has been launched in strengths of 50mg, 200mg and Terbinafine of 125mg. The products have a market size of around 400 million dollars and 300 million dollars respectively in Japan, for the above dosage forms, Ranbaxy said in a statement.
The products would be marketed and promoted jointly by Nippon Chemiphar and Nihon Pharmaceutical and sold in Japan under the Ranbaxy/Nihon Pharmaceutical Industry Ltd label.
"It is our earnest intention to leverage the advantage of an early entry in the progressive opening up of the generic Pharma market of Japan. We intend to rapidly introduce an array of generic therapies from our global portfolio," Ranbaxy s CEO and Managing Director Malvinder Mohan Singh said.
Ranbaxy had entered the Japanese market in the year 2002 through a strategic alliance with Nippon Chemiphar, a mid sized research pharmaceutical company.
In July 2005, the JV between the two companies had introduced its first co-developed product Vogseal O.2mg and 0.3mg tablets for the treatment of diabetes.
Last year, Ranbaxy had also increased its equity stake in Nihon Pharmaceutical, making it a 50:50 joint venture between the company and Nippon Chemiphar.